Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $71.40

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned an average recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $71.40.

A number of research firms have recently issued reports on ARCT. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday. Leerink Partners initiated coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They set an “outperform” rating and a $70.00 target price on the stock. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 15.30% of the company’s stock.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. Nordea Investment Management AB acquired a new stake in shares of Arcturus Therapeutics during the first quarter worth $1,846,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Arcturus Therapeutics by 22.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after acquiring an additional 286,546 shares during the period. Empire Life Investments Inc. purchased a new stake in Arcturus Therapeutics during the 3rd quarter valued at about $3,498,000. XTX Topco Ltd purchased a new stake in Arcturus Therapeutics during the 2nd quarter valued at about $596,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Arcturus Therapeutics in the second quarter valued at about $718,000. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT opened at $19.63 on Tuesday. The business’s 50 day moving average is $20.61 and its 200 day moving average is $24.23. Arcturus Therapeutics has a 52-week low of $17.26 and a 52-week high of $45.00.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.